5 Stocks Ready to Break Out: AMED, ARTX, EBIX, FXEN, PTIE

Trading stocks that trigger major breakouts can lead to massive profits. Once a stock trends to a new high, or takes out a prior overhead resistance point, then it's free to find new buyers and momentum players that can ultimately push the stock significantly higher.

One example of a successful breakout trade I flagged recently was renewable energy player Hanwha Solarone (HSOL), which I featured in Sept. 26's "5 Stocks Ready to Breakouts" at around $4.10 a share. I mentioned in that piece that shares of HSOL were uptrending strong over last few months, with shares making mostly higher lows and higher highs, which is bullish technical price action. That move was starting to push HSOL within range of triggering a big breakout trade above its 52-week high at $4.28 a share.  (more)

Please share this article

OIL Elliott Wave Analysis : Corrective Pullback With In Uptrend

OIL Daily
Few weeks back oil reversed sharply from the 112 high when a five wave rally from 91.00 area completed a larger degree of an extended wave 3). As such, the contra-trend reaction is called a corrective retracement that could now be bottoming. We are tracking red wave 4) that may look for a support around 50% Fibonacci retracement level compared to wave 3); that’s one of the most important Fibonacci levels when you are looking a reversal point. As such, be aware of a turning point to the upside.

OIL 4h
On 4h Chart Crude oil reached new low last week around 100 mark which is a strong psychological price that could react as a support. We also see the wave pattern which is pointing for a turning point. The latest count shows idea of an ending diagonal placed in wave C position that is final leg of a corrective retracement from 112. Bullish divergence on the RSI also suggests that lows are near. We however want to see a strong bounce through the upper channel line to confirm a bullish reversal.  (more)
Please share this article

“The Financial System Was Within Hours Of Absolute Collapse”

kingworldnews.com / October 21, 2013
Today KWN is pleased to share an incredibly powerful piece which exposes the frightening fact that “the financial system was within hours (and a few phone calls) of an absolute collapse.”  This masterpiece from 50-year veteran Art Cashin, who is Director of Floor Operations at UBS ($650 billion under management).  Not only does Cashin write about how close the system was to complete collapse, but he also describes his firsthand experiences from that frightening moment in time.

October 21 (King World News) – “On this day (-2) in 1987 (that’s 26 years ago, if you are burdened with a graduate degree), the NYSE had one of its most dramatic trading days in its 220 year history.
It suffered its largest single day percentage loss (22%) and its largest one day point loss up until that day (508 points).  No one who was on the floor that day will ever forget it.  While it was an unforgettable single day, there were months of events that went into its making.
READ MORE

Please share this article

Alasdair Macleod: Currency Crisis Dead Ahead

Introducing the ‘Fiat Money Quantity’ measure

This week’s podcast interview introduces a new monetary measurement developed by Alasdair Macleod: the ‘Fiat Quantity of Money’, or FMQ.
Alasdair explains how FMQ is derived, as well as what it can tell us about the true levels of fiat money supply. In the case of the dollar, it reveals that levels are far above what is commonly appreciated – so far, in fact, that a currency crisis could arrive sooner than even many dollar bears expect.
What ‘Fiat Money Quantity’ (FMQ) Is Signaling
I started off with the desire to put together a metric of money which allows me to compare sound money with fiat money. My approach to this was to look at what happens in how fiat money was created.
Read More @ PeakProsperity.com
Please share this article

The Hain Celestial Group, Inc. (NASDAQ: HAIN)

The Hain Celestial Group, Inc., together with its subsidiaries, manufactures, markets, distributes, and sells organic and natural products. The company offers grocery products comprising infant formula, infant, toddler and kids foods, non-dairy beverages and frozen desserts, flour and baking mixes, hot and cold cereals, pasta, condiments, cooking and culinary oils, granolas, granola and cereal bars, canned, chilled fresh, aseptic and instant soups, greek-style yogurt, chilis, packaged grains, chocolate, and nut butters. It also provides cold-pressed juices, chilled hot-eating and frozen desserts, cookies, crackers, gluten-free frozen entrees and bars, frozen pastas and ethnic meals, frozen fruit and vegetables, cut fresh fruit, refrigerated and frozen soy protein meat-alternative products, tofu, seitan and tempeh products, jams, fruit spreads and jelly, honey, and marmalade products, as well as other food products. Further, it provides personal care products comprising skin, hair and oral care, deodorants, baby care items, diapers, acne treatment, body washes, and sunscreens.
To review Hain's stock, please take a look at the 1-year chart of HAIN (The Hain Celestial Group, Inc.) below with my added notations:
Over the last (8) months HAIN has consistently moved higher. Since February though, the stock has formed a trendline of support (blue). Always remember that any (2) points can start a trendline, but it's the 3rd test and beyond that confirm its importance. HAIN confirmed its trendline support earlier this week. In addition, the stock has formed a trendline of resistance over the last (2) months (red). At some point, one of these lines has to break.

The Tale of the Tape: HAIN has created (2) trendlines to watch. A long position could be entered on a pullback to trendline support or on a break through trendline resistance. A short position could be entered on HAIN at trendline resistance or if the stock were to break the trend line support.
Please share this article

Is Santarus :SNTS a Buy?

The company’s treatments for colitis, angioedema, and travelers’ diarrhea could triple—that’s right, triple—the company’s 2012 revenue.

How can this be?

1. On January 14, 2013, the FDA approved its colitis treatment—pushing share prices 11% higher.
   
   
2. In the five months since the company’s colitis treatment was launched, the company has seen sales jump $22 million, and we expect revenues to double again by year’s end.
   
   
3. What’s more, the company’s new acid reflux product has one key advantage over its competitors: It offers the longest lasting acid control in the market—nearly 19 hours. The results will drive millions more in annual sales and earnings, not just for the next 90 days but for years to come.
   
   
4. In addition, the company’s anti-diabetes agent just received a huge endorsement from the AACE (American Academy of Clinical Endocrinologists), whose guidelines doctors use in prescribing. With the annual diabetes market estimated at $35 billion, that’s like winning a $100 million lottery every year as tens of thousands of doctors begin to prescribe this company’s new treatments over the competition.
   
   
5. As if that weren’t exciting enough, the company’s angioedema treatment just received orphan drug status from the FDA. As a result, the company will now receive millions of dollars in tax incentives, plus enhanced patented production and marketing rights—not to mention subsidies for its clinical research.

This is why the company’s stock price has soared 392% since I first recommended it in March 2012. With the analyst community expecting the company to declare another 150% earnings growth come November, we see the upward trajectory on this stock continuing for some time to come.

This is why, if you can add this one to your holdings before it declares earnings—and before the pension funds pile in—you could easily grab its next 100% gain by the end of the year.

Santarus Inc...

• Has registered 89% sales growth and 2,032% earnings growth year over year,
  
  
• Has analysts forecasting another 154% earnings rise come November,
  
  
• Has a forward P/E ratio of—get this—just 15, and that’s after the stock has handed my readers 392% gains in 19 months,
  
  
• Has a market cap of under $2 billion,
  
  
• Has one of the strongest buy ratings of any of our stocks, and
  
  
• Has just reported a 7.8% sales surprise and a 72.2% earnings surprise and raised its full-year outlook to $1.61 to $1.65 per share from $0.72 to $0.81 per share.

Throw in the fact that ObamaCare is about to funnel another 31 million potential customers its way and you can see why I’m convinced beyond doubt the company is going to clobber Wall Street and double investors’ money again.

Please share this article

Full Moon Drives Nasdaq To New 2013 Highs

It’s hard to really trust the market moves when the Nasdaq screams higher and the Dow closes essentially flat and I want to point something out that could be key as we go into next week.

• Oct 18th – full moon (top?)
• Sept 19th – full moon (top in markets)
• July 22nd – (a congestion zone that became a top)
• June 23rd – bottom

My point here is that the full moon is often associated (at least in recent times) with an important reversal area for the Dow. Add in the fact the Nasdaq is really over-extended and enthusiasm for tech stocks after Google’s earnings should be at highs, and you have a recipe for a pullback. I’m not bearish as I am more indifferent to what is going on in the markets. I’m waiting for some sort of game-breaker move to the upside to get long (and we may have it after today, but it will be key to see how the Nasdaq performs in the coming days) or I was waiting for a decent pullback to get long.

Please share this article